🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Intuitive Surgical target raised to $520 on strong da Vinci sales

EditorLina Guerrero
Published 07/23/2024, 02:42 PM
ISRG
-

On Tuesday, Intuitive Surgical (NASDAQ:ISRG) saw its price target increased to $520 from the previous $450, while retaining a Buy rating, according to a report from Argus. The firm acknowledged Intuitive Surgical as a frontrunner in the rapidly expanding sector of robot-assisted surgery, highlighting the company's recent successes and future potential.

The upgrade comes in light of a notable increase in the usage of the da Vinci surgical robotic systems, which saw a 17% rise in procedural volume worldwide in the last quarter, surpassing the consensus estimate of 15.4%. This surge is seen as an indicator of future capital equipment purchases by hospitals and ambulatory surgery centers.

Intuitive Surgical has also revised its full-year 2024 guidance upward for procedural volume growth, reflecting confidence in the continued adoption of its technology. The company's ongoing research efforts aim to substantiate the positive effects of the da Vinci system on surgical outcomes.

Investments by the company are set to continue, with a focus on expanding surgeon training, developing new products and functionalities, and conducting academic studies to validate the clinical efficacy and benefits of the da Vinci system. These strategic initiatives are expected to drive future growth for Intuitive Surgical.

The decision by Argus to raise the target price to $520 from $450 is based on the company's solid performance and promising outlook, as it cements its position at the forefront of innovation in robot-assisted surgical procedures.

In other recent news, Intuitive Surgical has been making waves with its strong second-quarter performance. The company's revenue and earnings per share (EPS) exceeded expectations, driven by a 17% increase in procedures and the placement of 70 da Vinci surgical systems. This led to several analyst firms, including Piper Sandler, Baird, RBC Capital, and BTIG, raising their price targets for Intuitive Surgical. However, Evercore ISI reduced its price target to $410, but retained an 'In Line' rating.

The company's performance has also led to an upward revision of its full-year 2024 guidance, raising the midpoint of its worldwide procedure growth outlook to a range of 15.5-17.0%, up from the previous forecast of 14.0-17.0%. Additionally, the company improved its gross margin projections and reduced its operating expense targets.

Truist Securities has maintained a Buy rating and increased the firm's price target on the company's shares from $515 to $520. This follows Intuitive Surgical's second-quarter revenue and EPS that surpassed expectations, driven by a significant uptick in procedures and system sales, including the addition of 70 new da Vinci 5 (D5) systems. The company's performance indicates a trajectory to surpass Truist's previous forecast of 60 D5 placements for the year 2024.

InvestingPro Insights

Intuitive Surgical's (NASDAQ:ISRG) recent achievements and upward momentum are reflected in its robust financial metrics. With a market capitalization of $163.0 billion, the company showcases its significant presence in the medical technology industry. Investors should note the high P/E ratio of 77.39, which indicates the market's high expectations for future earnings growth, a sentiment echoed by the 23 analysts who have revised their earnings upwards for the upcoming period. Additionally, with a revenue growth of 13.62% in the last twelve months as of Q2 2024, Intuitive Surgical demonstrates its capability to expand its market reach and increase its sales effectively.

Strategic investors might also consider the company's strong return over the last three months, which stands at an impressive 22.29%, signaling robust investor confidence. Moreover, Intuitive Surgical operates with a moderate level of debt, ensuring financial flexibility. For those interested in diving deeper into the company's financial health and future prospects, InvestingPro provides an array of InvestingPro Tips, including a total of 17 additional tips available at https://www.investing.com/pro/ISRG. To access these insights and more, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.